NEUCA S.A. Stock

Equities

NEU

PLTRFRM00018

Pharmaceuticals

Market Closed - Warsaw S.E. 11:55:55 2024-05-24 am EDT 5-day change 1st Jan Change
969 PLN +0.73% Intraday chart for NEUCA S.A. +2.98% +4.76%
Sales 2024 * 13.02B 3.32B Sales 2025 * 13.69B 3.49B Capitalization 4.33B 1.11B
Net income 2024 * 188M 48M Net income 2025 * 230M 58.72M EV / Sales 2024 * 0.35 x
Net Debt 2024 * 278M 70.97M Net Debt 2025 * 169M 43.22M EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 4,633
Yield 2024 *
1.55%
Yield 2025 *
2.06%
Free-Float 33.85%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.73%
1 week+2.98%
Current month+6.25%
1 month+8.27%
3 months+12.15%
6 months+21.58%
Current year+4.76%
More quotes
1 week
934.00
Extreme 934
969.00
1 month
903.00
Extreme 903
969.00
Current year
790.00
Extreme 790
969.00
1 year
630.00
Extreme 630
969.00
3 years
527.00
Extreme 527
969.00
5 years
272.00
Extreme 272
969.00
10 years
182.10
Extreme 182.1
969.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 00-12-31
Founder - 89-12-31
Director of Finance/CFO - 10-07-31
Members of the board TitleAgeSince
Founder - 89-12-31
Director/Board Member 72 09-06-15
Founder - 89-12-31
More insiders
Date Price Change Volume
24-05-24 969 +0.73% 457
24-05-23 962 +2.23% 730
24-05-22 941 -0.95% 288
24-05-21 950 +0.96% 532
24-05-20 941 0.00% 128

Delayed Quote Warsaw S.E., May 24, 2024 at 11:55 am EDT

More quotes
Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
969 PLN
Average target price
974.7 PLN
Spread / Average Target
+0.58%
Consensus

Quarterly revenue - Rate of surprise